Protective effect of pharmacological castration on metabolic perturbations and cardiovascular disease in the hyperglycemic male ApoE-/-:Ins2+/Akita mouse model.

abstract：BACKGROUND:Understanding the mechanisms driving disease progression is fundamental to identifying new therapeutic targets for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC). Owing to the prevalence of bone metastases in mCRPC, obtaining sufficient tumor tissue for analysis has histori...

journal_title：Prostate cancer and prostatic diseases

authors： McKay RR,Zukotynski KA,Werner L,Voznesensky O,Wu JS,Smith SE,Jiang Z,Melnick K,Yuan X,Kantoff PW,Montgomery B,Balk SP,Taplin ME

更新日期：2014-12-01 00:00:00

abstract：BACKGROUND:The worldwide incidence of diabetes mellitus is rapidly increasing. There is recent interest in the influence of glucose metabolism on oncogenesis. We investigated the role of diabetes mellitus and the metabolic syndrome (MS) on prostate cancer development. METHODS:This study consisted of 11 541 men with co...

journal_title：Prostate cancer and prostatic diseases

authors： Lawrence YR,Morag O,Benderly M,Boyko V,Novikov I,Dicker AP,Goldbourt U,Behar S,Barchana M,Wolf I

更新日期：2013-06-01 00:00:00

abstract：INTRODUCTION:Approximately 85% of patients who die from prostate cancer present the spread of bone metastases. Even though the radiological appearance of such metastases is osteoblastic, it is now known that these lesions coexist in their microenvironment with blastic and lytic lesions. The process always begins with b...

journal_title：Prostate cancer and prostatic diseases

authors： Rodrigues P,Hering F,Campagnari JC

更新日期：2004-01-01 00:00:00

abstract：BACKGROUND:The combination of abiraterone acetate and prednisone (AA/P) is used to treat metastatic prostate cancer, but molecular predictors of treatment response are not well elucidated. We evaluated plasma circulating tumor DNA- (ctDNA-) based copy number alterations (CNAs) to determine treatment-related predictive ...

journal_title：Prostate cancer and prostatic diseases

authors： Du M,Tian Y,Tan W,Wang L,Wang L,Kilari D,Huang CC,Wang L,Kohli M

更新日期：2020-12-01 00:00:00

abstract：BACKGROUND:The value of radical prostatectomy (RP) as an approach for very high-risk prostate cancer (PCa) patients is controversial. To examine the risk of 10-year cancer-specific mortality (CSM) and other-cause mortality (OCM) according to clinical and pathological characteristics of very high-risk cT3b/4 PCa patient...

journal_title：Prostate cancer and prostatic diseases

authors： Moltzahn F,Karnes J,Gontero P,Kneitz B,Tombal B,Bader P,Briganti A,Montorsi F,Van Poppel H,Joniau S,Spahn M

更新日期：2015-03-01 00:00:00

abstract：:Chronic fatigue (CF) is a distressing symptom that follows cancer treatment; however, it has rarely been studied in hormone-naïve prostate cancer survivors after radical prostatectomy (RP) or definitive radiotherapy (RAD). We investigated CF in prostate cancer survivors after RP or RAD as monotherapy and explored asso...

journal_title：Prostate cancer and prostatic diseases

authors： Kyrdalen AE,Dahl AA,Hernes E,Cvancarova M,Fosså SD

更新日期：2010-06-01 00:00:00

abstract：:Prescription sales of testosterone have risen considerably over the last decade and are likely to continue to grow as further preparations become available. Testosterone promotes existing prostate cancer; however, concern does exist as to whether or not testosterone therapy induces prostate cancer. The aim of this art...

journal_title：Prostate cancer and prostatic diseases

authors： Gould DC,Kirby RS

更新日期：2006-01-01 00:00:00

abstract：:This corrects the article DOI: 10.1038/pcan.2017.5. ...

journal_title：Prostate cancer and prostatic diseases

authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

更新日期：2017-12-01 00:00:00

abstract：BACKGROUD:The European Organization for Research and Treatment of Cancer (EORTC) trial 22,911 reported 74% 5-year biochemical disease-free survival (bDFS) in patients with prostate carcinoma treated with radical prostatectomy (RP) followed by postoperative radiotherapy (RT). This study aimed to improve these outcomes b...

journal_title：Prostate cancer and prostatic diseases

authors： Mantini G,Siepe G,Alitto AR,Buwenge M,Nguyen NP,Farioli A,Schiavina R,Catucci F,Deodato F,Fionda B,Frascino V,Macchia G,Ntreta M,Padula GDA,Arcelli A,Cammelli S,Rambaldi GZ,Cilla S,Valentini V,Morganti AG

更新日期：2018-11-01 00:00:00

abstract：:This study investigated the hypothesis that, in benign prostatic hyperplasia (BPH), upregulated oestrogen receptors (ER) and the action of androgens differentially regulate expression of stromal growth factors. Eight human prostatic stromal cell strains were subjected to a procedure to upregulate their ER by exposing ...

journal_title：Prostate cancer and prostatic diseases

authors： Smith P,Rhodes NP,Ke Y,Foster CS

更新日期：2004-01-01 00:00:00

abstract：:In addition to androgen, autonomic nerves may be involved in prostatic function. As patients with spinal cord injury (SCI) have impaired innervation of the prostate, the prostate volume and prostate-specific antigen (PSA) level in patients with SCI may be different from those of healthy men. Experiments in rats with S...

journal_title：Prostate cancer and prostatic diseases

authors： Shim HB,Jung TY,Lee JK,Ku JH

更新日期：2006-01-01 00:00:00

abstract：BACKGROUND:Berbamine (BBM) has been reported with antitumor activities. BBM inhibited the growth of prostate cancer (PCa) cells and caused vacuolization of mitochondria in preliminary study. We hypothesized BBM could enhance apoptosis of PCa cells through mitochondrial pathway. METHODS:Growth of PC-3 and LNCaP cells t...

journal_title：Prostate cancer and prostatic diseases

authors： Zhao Y,Lv JJ,Chen J,Jin XB,Wang MW,Su ZH,Wang LY,Zhang HY

更新日期：2016-12-01 00:00:00

abstract：BACKGROUND:Focal therapy is an emerging mini-invasive treatment modality for localized prostate cancer aimed to reduce the morbidity associated with radical therapy while maintaining optimal cancer control. We report the mid-term oncological and functional results of primary hemiablation high-intensity focused ultrasou...

journal_title：Prostate cancer and prostatic diseases

authors： van Velthoven R,Aoun F,Marcelis Q,Albisinni S,Zanaty M,Lemort M,Peltier A,Limani K

更新日期：2016-03-01 00:00:00

abstract：:The relationships between serum level of testosterone (T) and prostate cancer (PCa) are complex. The present study evaluated whether presence of PCa alters serum T levels. Subjects were 125 patients with clinically localized PCa treated using radical prostatectomy (RP), for whom pretreatment T levels were recorded. We...

journal_title：Prostate cancer and prostatic diseases

authors： Imamoto T,Suzuki H,Yano M,Kawamura K,Kamiya N,Araki K,Komiya A,Naya Y,Shiraishi T,Ichikawa T

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:Patients with bone metastases secondary to prostate cancer are predisposed to skeletal-related events (SREs), including spinal cord compression, pathological fracture, surgery to bone and radiotherapy to bone. The objective of this study was to document current patterns of healthcare utilization and costs of...

journal_title：Prostate cancer and prostatic diseases

authors： Hagiwara M,Delea TE,Saville MW,Chung K

更新日期：2013-03-01 00:00:00

abstract：:The objective of this work is to describe the profile of prevalent and incident populations suffering from lower urinary tract symptoms (LUTS) suggestive of benign prostatic obstruction (BPO) and to analyse the management of care by 620 general practitioners (GPs) in France in 1997 and 1998. Patient records were extra...

journal_title：Prostate cancer and prostatic diseases

authors： Vallancien G,Pariente P

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:To compare prostate cancer detection rates between transrectal ultrasound (TRUS) prostate biopsy and transperineal template prostate biopsy (TPTPB) in biopsy naïve men. TRUS biopsy is still regarded as gold standard for prostate cancer diagnosis. TPTPB has been shown to improve prostate cancer detection in m...

journal_title：Prostate cancer and prostatic diseases

authors： Nafie S,Mellon JK,Dormer JP,Khan MA

更新日期：2014-06-01 00:00:00

abstract：:Antiandrogen therapy is an important modality in the treatment of prostate cancer. Recent research into the role of angiogenesis in tumour growth and metastasis has uncovered links between antiandrogen therapy, radiation therapy and angiogenesis, which have exciting implications for the treatment of prostate cancer. A...

journal_title：Prostate cancer and prostatic diseases

authors： Woodward WA,Wachsberger P,Burd R,Dicker AP

更新日期：2005-01-01 00:00:00

abstract：:Prostate cancer patients' management demands prioritization, adjustments, and a tailored approach during the unprecedented SARS-CoV-2 pandemic. Benefit of care from treatment must be carefully weighed against the potential of infection and morbidity from COVID-19. Furthermore, urologists need to be cognizant of their ...

journal_title：Prostate cancer and prostatic diseases

authors： Obek C,Doganca T,Argun OB,Kural AR

更新日期：2020-09-01 00:00:00

abstract：INTRODUCTION:Treatment options for lymph node positive prostate cancer are limited. We retrospectively compared patients who underwent external radiotherapy (ERT) to patients treated by radical prostatectomy (RPX). MATERIALS AND METHODS:A total of 102 lymph node positive patients from the RPX series at Ulm University ...

journal_title：Prostate cancer and prostatic diseases

authors： Kuefer R,Volkmer BG,Loeffler M,Shen RL,Kempf L,Merseburger AS,Gschwend JE,Hautmann RE,Sandler HM,Rubin MA

更新日期：2004-01-01 00:00:00

abstract：:Stromal expression of some matrix metalloproteinases (MMPs) has been associated with increasing tumour burden in prostate cancer. We investigated the expression of mRNA (by RT-PCR) and protein (by zymography and western blotting) of MMPs and endogenous inhibitors (tissue inhibitors of metalloproteinases, TIMPs) in two...

journal_title：Prostate cancer and prostatic diseases

authors： Daja MM,Niu X,Zhao Z,Brown JM,Russell PJ

更新日期：2003-01-01 00:00:00

abstract：OBJECTIVE:To survey UK urologists and radiation oncologists in the evaluation and treatment of localised prostate cancer in the adjuvant and salvage setting. METHODS:Postal questionnaires were mailed to 292 urologists and 98 radiation oncologists in the UK. RESULTS:In all, 188 (48%) questionnaires were returned. In t...

journal_title：Prostate cancer and prostatic diseases

authors： Lee LW,Clarke NW,Ramani VA,Cowan RA,Wylie JP,Logue JP

更新日期：2005-01-01 00:00:00

abstract：BACKGROUND:To determine the evolution of prostatic multi-parametric magnetic resonance imaging (mp-MRI) signal following transrectal ultrasound (TRUS)-guided biopsy. METHODS:Local ethical permission and informed written consent was obtained from all the participants (n=14, aged 43-69, mean 64 years). Patients with a c...

journal_title：Prostate cancer and prostatic diseases

authors： Latifoltojar A,Dikaios N,Ridout A,Moore C,Illing R,Kirkham A,Taylor S,Halligan S,Atkinson D,Allen C,Emberton M,Punwani S

更新日期：2015-12-01 00:00:00

abstract：BACKGROUND:Surgery and radiation-based therapies are standard management options for men with clinically localized high-risk prostate cancer (PCa). Contemporary patterns of care are unknown. We hypothesize the use of surgery has steadily increased in more recent years. METHODS:Using the National Cancer Data Base for 2...

journal_title：Prostate cancer and prostatic diseases

authors： Weiner AB,Matulewicz RS,Schaeffer EM,Liauw SL,Feinglass JM,Eggener SE

更新日期：2017-09-01 00:00:00

abstract：:New approaches to treat prostate cancer (PCA) are utilizing gene therapy and aim to correct the disease at the genetic level. Getting a gene efficiently into the target cell is the subject of much interest. We used a holmium laser for transfecting rat PCA cells with the reporter gene pEGFP. By FACS analysis and fluore...

journal_title：Prostate cancer and prostatic diseases

authors： Sagi S,Knoll T,Trojan L,Schaaf A,Alken P,Michel MS

更新日期：2003-01-01 00:00:00

abstract：:Randomized data from SWOG 8794 and EORTC 22911 confirm the benefit of post-operative radiation therapy (RT) for selected patients with pT3 prostate cancer (CaP) after radical prostatectomy (RP). However, data regarding the potential benefit of RT for patients post-RP with positive lymph node (+LN) involvement are limi...

journal_title：Prostate cancer and prostatic diseases

authors： Johnstone PA,Assikis V,Goodman M,Ward KC,Riffenburgh RH,Master V

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Patients with high-risk prostate cancer have an increased likelihood of experiencing a relapse following radical prostatectomy (RP). We previously conducted three neoadjuvant androgen-deprivation therapy (ADT) trials prior to RP in unfavorable intermediate and high-risk disease. METHODS:In this analysis, we...

journal_title：Prostate cancer and prostatic diseases

authors： McKay RR,Montgomery B,Xie W,Zhang Z,Bubley GJ,Lin DW,Preston MA,Trinh QD,Chang P,Wagner AA,Mostaghel EA,Kantoff PW,Nelson PS,Kibel AS,Taplin ME

更新日期：2018-09-01 00:00:00

abstract：:Rectum and bladder are the crucial organs at risk for curative radiation therapy of localized prostate cancer. We analyzed the incidence, profile and time course of late rectal radiation toxicity. A total of 320 patients with T1-3 prostate cancer were treated with three-dimensional conformal radiation therapy (3D-CRT)...

journal_title：Prostate cancer and prostatic diseases

authors： Odrazka K,Dolezel M,Vanasek J,Vaculikova M,Zouhar M,Sefrova J,Paluska P,Vosmik M,Kohlova T,Kolarova I,Macingova Z,Navratil P,Brodak M,Prosvic P

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND:Large multicenter studies comparing outcomes between TURP and photoselective vaporization of the prostate (PVP) are sparse, with no studies having compared the influence of trainee involvement on these outcomes. Our objectives were to assess 30-day outcomes after TURP and PVP with respect to trainee involvem...

journal_title：Prostate cancer and prostatic diseases

authors： Olcese SP,Derosa R,Kern SQ,Lustik MB,Sterbis JR,McMann LP

更新日期：2014-09-01 00:00:00

abstract：BACKGROUND:Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we exami...

journal_title：Prostate cancer and prostatic diseases

authors： Den RB,Santiago-Jimenez M,Alter J,Schliekelman M,Wagner JR,Renzulli Ii JF,Lee DI,Brito CG,Monahan K,Gburek B,Kella N,Vallabhan G,Abdollah F,Trabulsi EJ,Lallas CD,Gomella LG,Woodlief TL,Haddad Z,Lam LL,Deheshi S,Wa

更新日期：2016-12-01 00:00:00